-
Uncategorized1 month ago
Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapy
The FDA’s extension will give reviewers more time to review a major amendment to Biogen and Eisai’s application for a subcutaneous induction formulation of Alzheimer’s therapy...
-
Uncategorized1 month ago
Lilly invests $4.5B in Indiana manufacturing, opens doors of 1st genetic medicine site
Eli Lilly’s latest manufacturing expansion will support production of obesity blockbusters and next-gen assets, while the new Lilly Lebanon Advanced Therapies site will take experimental genetic...
-
Uncategorized1 month ago
Gilead sets blockbuster bar for Yeztugo’s first full year on the market
With initial patients coming back for their second dose of Gilead’s twice-yearly PrEP injection, the pharma thinks the shot will hit $1 billion in sales this...
-
Uncategorized1 month agoThe aging scientific workforce collides with rising fabricating citations in medical journals
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. The AC broke in STAT’s NYC bureau, so...
-
Uncategorized1 month ago
Natalie Holles’ next move after Third Harmonic shutdown; Mark Alles passes the torch at ADC biotech
→ It didn’t take long for Natalie Holles to rebound after the decision to wind down operations at her previous company. She has replaced Elisabet de...
-
Uncategorized1 month agoOpinion: STAT+: Medicare’s new RAPID pathway is a breakthrough for adults. Children are still waiting
In late April, the Centers for Medicare and Medicaid Services and the Food and Drug Administration announced the Regulatory Alignment for Predictable and Immediate Device, or...
-
Uncategorized1 month ago
Odyssey raises more than $300M as biotech goes public in IPO
Odyssey Therapeutics pulled together $279 million from its initial public offering, the autoimmune disease drug developer said Thursday night. With its IPO now priced, Odyssey is...
-
Uncategorized1 month agoOdyssey, on second try, snags $279M in an IPO
After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech stock offerings. Read More
-
Uncategorized1 month ago
Macrophages Use Cell Volume Changes to Sense Danger and Amplify Inflammation
Macrophages are often described as the immune system’s first responders, but new work suggests they are also remarkably attuned to the physical state of their environment....
-
Uncategorized1 month agoFraudulent citations, blamed on AI hallucinations, are becoming more common in research papers
Citations in academic papers are intended to ground research in the work that preceded it, over time creating something of a family tree explaining the roots...
